Report #2833237

Overview

Sex

Unknown

Age

Age unknown

State

—

Recovered

Unknown

Vaccinated

—

Onset

—

Days to onset

—

Hospital days

—

Symptoms (1)

Symptom narrative

Priorix probable intramuscular administration; This non-serious case was reported by a other health professional via call center representative and described the occurrence of subcutaneous injection formulation administered by other route in a patient who received MMR (Priorix) for prophylaxis. On an unknown date, the patient received Priorix (intramuscular). On an unknown date, an unknown time after receiving Priorix, the patient experienced subcutaneous injection formulation administered by other route (Verbatim: Priorix probable intramuscular administration). The outcome of the subcutaneous injection formulation administered by other route was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 17-MAR-2025 A pharmacist wanted to know what would happen if Priorix was administered intramuscularly. The agent asked if this administration had already occurred, which led subcutaneous injection formulation administered by other route but the health care provider only commented that he did not have confirmation till the time of reporting and therefore could not provide the adverse event data.